Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

516 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial.
Frias J, Virdi N, Raja P, Kim Y, Savage G, Osterberg L. Frias J, et al. J Med Internet Res. 2017 Jul 11;19(7):e246. doi: 10.2196/jmir.7833. J Med Internet Res. 2017. PMID: 28698169 Free PMC article. Clinical Trial.
A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections.
Frias JP, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Edelman SV. Frias JP, et al. J Diabetes Sci Technol. 2011 Jul 1;5(4):887-93. doi: 10.1177/193229681100500410. J Diabetes Sci Technol. 2011. PMID: 21880230 Free PMC article. Clinical Trial.
Continuous subcutaneous insulin infusion in patients with type 2 diabetes: a cohort study to establish the relationship between glucose control and plasma oxidized low density lipoprotein.
Megson IL, Treweeke AT, Shaw A, MacRury SM, Setford S, Frias JP, Anhalt H. Megson IL, et al. J Diabetes Sci Technol. 2015 May;9(3):573-80. doi: 10.1177/1932296815570359. Epub 2015 Feb 3. J Diabetes Sci Technol. 2015. PMID: 25652563 Free PMC article. Clinical Trial.
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Frías JP, et al. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Lancet Diabetes Endocrinol. 2016. PMID: 27651331 Clinical Trial.
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG. Rosenstock J, et al. Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Diabetes Obes Metab. 2018. PMID: 28857451 Clinical Trial.
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Aronson R, et al. Diabetes Obes Metab. 2018 Jun;20(6):1453-1460. doi: 10.1111/dom.13251. Epub 2018 Feb 23. Diabetes Obes Metab. 2018. PMID: 29419917 Free PMC article. Clinical Trial.
516 results
Jump to page
Feedback